After the validation of GM‐protac efficacy on the cellular function of osimertinib‐resistant lung cancer, we then further analyzed the potential mechanisms of GM‐protac on HDAC and EGFR signaling pathways in H1975‐OR cells. This evidence concerns the gene HDAC9 and lung carcinoma.